The REAL Meats Act amends section 403 of the Federal Food, Drug, and Cosmetic Act to require that products that are cell‑cultured or meat analogues carry a qualifying term immediately before the product name that clearly communicates the product's nature (examples in the text include 'cell‑cultured', 'lab‑grown', 'analogue', 'meatless', and 'made from plants'). It also creates a specific rule for products that use species names (e.g., 'chicken', 'beef', 'pork'), requiring the narrower qualifiers 'cell‑cultured', 'lab‑grown', 'analogue', or 'imitation' in front of those names.
The bill supplies statutory definitions for 'analogue product' and 'cell‑cultured product' and ties 'meat,' 'meat food product,' and 'poultry' to existing definitions in Title 9 of the CFR and the Federal Meat Inspection Act and Poultry Products Inspection Act. For compliance officers, product teams, and regulators, the change converts commonly used marketing language into a legal obligation that will drive label redesigns, regulatory determinations about jurisdictional scope, and new enforcement exposures based on 21 U.S.C. 343 (misbranding).
At a Glance
What It Does
The bill adds a new subsection (z) to 21 U.S.C. 343 requiring that cell‑cultured and analogue products bear a qualifying term immediately before the product name that communicates the product's contents, and it mandates specific qualifiers when an animal species name appears in the product name. It also inserts statutory definitions for key terms and cross‑references existing CFR and meat/poultry statutes.
Who It Affects
Manufacturers of cell‑cultured meat and poultry, plant‑based 'analogue' producers, food marketers and retailers, and federal regulators (primarily FDA, with cross‑references to USDA’s FMIA and PPIA definitions). Product designers, legal teams, and labeling vendors will face new compliance tasks.
Why It Matters
By putting labeling rules into the FD&C Act, the bill creates a statutory basis for FDA misbranding actions against products whose names lack the required qualifiers and clarifies (but does not resolve) the boundary between FDA labeling rules and USDA inspection triggers. The change raises immediate commercial and legal stakes for how novel protein products are named and marketed.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The REAL Meats Act is short and focused: it inserts a new paragraph into the FD&C Act’s misbranding section to force upfront qualifiers on certain novel protein products. At a minimum, any product the bill treats as a 'cell‑cultured product' or an 'analogue product' must display a qualifying term immediately before the product name that communicates the nature of the product.
The bill gives examples—'cell‑cultured,' 'lab‑grown,' 'analogue,' 'meatless,' and 'made from plants'—but uses 'such as' language, which leaves room for other equivalent terms.
When a manufacturer uses an animal species name in a product name—explicitly listing 'chicken', 'turkey', 'beef', or 'pork' and extending to 'another species or kind of animal'—the statute narrows the permitted qualifiers: the label must place immediately before the species name one of the terms 'cell‑cultured', 'lab‑grown', 'analogue', or 'imitation.' That creates a two‑tier obligation: a general qualifier requirement for novel products, and a stricter naming rule where species words are used.The bill defines the covered product categories. An 'analogue product' is a food made by combining processed plants, insects, or fungi with additives to approximate the sensory or chemical characteristics of a specific type of meat or poultry, and that lacks meat/poultry at levels that would trigger inspection under the Federal Meat Inspection Act (FMIA) and the Poultry Products Inspection Act (PPIA).
A 'cell‑cultured product' is tissue produced by harvesting animal cells and growing them in a laboratory medium. The statute also borrows existing legal definitions for 'meat', 'meat food product', and 'poultry' from the CFR and FMIA/PPIA, and it explicitly excludes products already exempted under 9 C.F.R. 381.15.Operationally, the change converts commonly used marketing descriptors and packaging design choices into legal compliance issues.
Producers will need to decide which qualifying term to use, where and how to place it so it counts as 'immediately before the name,' and whether current ingredient formulations or low‑level animal content push a product into USDA inspection territory. Regulators will have to interpret the statutory phrases, determine enforcement priorities under the misbranding framework, and grapple with border cases at the intersection of FDA labeling law and USDA inspection jurisdiction.
The Five Things You Need to Know
The bill adds subsection (z) to 21 U.S.C. 343, making omission of a qualifying term before a product name a misbranding violation for cell‑cultured or analogue products.
If a product name includes an animal species (e.g.
'chicken', 'beef', 'pork'), the label must place immediately before that name one of: 'cell‑cultured', 'lab‑grown', 'analogue', or 'imitation'.
An 'analogue product' is defined as a plant/insect/fungus‑derived food combined with additives to approximate meat characteristics and that does not contain meat/poultry at levels that would trigger FMIA/PPIA inspection.
A 'cell‑cultured product' is defined as tissue produced by harvesting animal cells and replicating them in a growth medium in a laboratory to produce tissue.
The bill anchors its terminology to existing federal definitions by referencing 9 C.F.R. section 301.2 (meat), FMIA section 1(j) (meat food product), and PPIA section 4 and CFR 381.15 exemptions for poultry.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — 'REAL Meats Act'
This single‑line provision supplies the Act’s short title. Practically it signals the bill’s focus for rulemaking and litigation references but creates no operative compliance obligations.
New misbranding rules for cell‑cultured and analogue products
The core operative change is the insertion of subsection (z) into the FD&C Act’s misbranding statute. Paragraph (z)(1) imposes a general duty: if a product is cell‑cultured or an analogue, the label must bear a qualifying term that 'clearly communicates' the product’s contents and nature, and that term must appear immediately before the product name. The provision gives non‑exhaustive examples of acceptable qualifiers, which preserves some label flexibility but transfers interpretive work to regulators and courts.
Stricter rule when animal species appear in the product name
Paragraph (z)(2) adds a more prescriptive rule for product names that use species identifiers: only a short set of qualifiers is listed ('cell‑cultured', 'lab‑grown', 'analogue', or 'imitation') and must be placed immediately before the species term. This narrows marketing choices when manufacturers seek to borrow species names that traditionally fall under USDA inspection statutes.
Statutory definitions and cross‑references to FMIA/PPIA and CFR
Paragraph (z)(3) supplies working definitions for 'analogue product' and 'cell‑cultured product' and imports the legal meanings of 'meat', 'meat food product', and 'poultry' from existing federal regulations and statutes. Importantly, the analogue definition conditions coverage on whether an item contains meat/poultry at levels that trigger FMIA/PPIA inspection, creating an evidentiary and regulatory threshold that will determine which agency’s rules apply.
This bill is one of many.
Codify tracks hundreds of bills on Agriculture across all five countries.
Explore Agriculture in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers seeking transparency — the law requires clear, front‑of‑name qualifiers so shoppers can more easily distinguish lab‑grown and plant‑derived items from traditional meat.
- Conventional meat and poultry producers — clearer labeling for substitutes reduces the likelihood of consumer confusion and supports claims of distinct product categories.
- State and federal regulators — the statute supplies a specific statutory hook in the FD&C Act for enforcement and for drafting guidance about labeling of novel proteins.
Who Bears the Cost
- Cell‑cultured meat and tissue companies — they must redesign labels, potentially revise product names, and face heightened misbranding risk if qualifiers are judged insufficient or misleading.
- Plant‑based and insect/fungus 'analogue' producers — small firms will incur costs to validate that formulations do not trigger FMIA/PPIA inspection thresholds and to implement new labeling.
- Retailers and private‑label brands — shelf tags, point‑of‑sale descriptions, and packaging will need updates; retailers will also bear compliance risk for mislabeled items on display.
- Federal agencies (FDA and USDA) — the cross‑references to FMIA/PPIA create likely jurisdictional questions and administrative burdens as agencies interpret thresholds and enforce labeling rules.
Key Issues
The Core Tension
The central dilemma is transparency versus regulatory friction and commercial flexibility: the bill advances consumer clarity by forcing unmistakable qualifiers, but it simultaneously restricts how innovators name and market novel proteins, ties FDA labeling to USDA inspection thresholds, and pushes opaque interpretive decisions onto agencies and courts—trading clearer labels for greater compliance cost and legal uncertainty.
The bill leaves several implementation questions unresolved. It demands a qualifying term 'immediately before the name' but does not define formatting, type size, or prominence; those visual and typographic questions are the most likely grounds for disputes and litigation.
The statute furnishes examples of acceptable qualifiers using 'such as' language, which grants flexibility but also invites disagreement about which alternative phrases 'clearly communicate' the product’s nature. Compliance officers will want explicit FDA guidance on placement, prominence, and acceptable alternate terms.
A second structural ambiguity concerns the analogue definition’s reliance on whether a product contains meat or poultry 'at levels that would trigger inspection under' FMIA/PPIA. The bill does not define that measurement—percentage by weight, detectable presence, or processing thresholds—and it ties FDA labeling law to USDA inspection standards without resolving how the two agencies will coordinate.
That linkage creates predictable jurisdictional friction and leaves open evidentiary questions (how to test, what thresholds govern, and who certifies the result). Finally, the bill elevates commercial‑speech and trademark tension: requiring specific qualifiers immediately before product names may prompt constitutional challenges or disputes with branding strategies, particularly where a qualifier could be seen as disparaging or misleading in context.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.